Non-invasive detection of bilirubin concentrations during the first week of life in a low-resource setting along the Thailand-Myanmar border

dc.contributor.authorBancone G.
dc.contributor.authorGilder M.E.
dc.contributor.authorWin E.
dc.contributor.authorGornsawun G.
dc.contributor.authorMoo P.K.
dc.contributor.authorArchasuksan L.
dc.contributor.authorWai N.S.
dc.contributor.authorWin S.
dc.contributor.authorHanboonkunupakarn B.
dc.contributor.authorNosten F.
dc.contributor.authorCarrara V.I.
dc.contributor.authorMcGready R.
dc.contributor.correspondenceBancone G.
dc.contributor.otherMahidol University
dc.date.accessioned2024-10-22T18:23:51Z
dc.date.available2024-10-22T18:23:51Z
dc.date.issued2024-09-28
dc.description.abstractBackground Neonatal hyperbilirubinaemia (NH) is a common problem worldwide and is a cause of morbidity and mortality especially in low-resource settings. Methods A study was carried out at Shoklo Malaria Research Unit (SMRU) clinics along the Thailand-Myanmar border to evaluate a non-invasive test for diagnosis of NH in a low-resource setting. Performance of a transcutaneous bilirubinometer Dräger Jaundice Meter JM-105 was assessed against routine capillary serum bilirubin testing (with BR-501 microbilirubinometer) before phototherapy during neonatal care in the first week of life. Results were analysed by direct agreement and by various bilirubin thresholds used in clinical practice. Total serum bilirubin was also measured in cord blood at birth and tested for prediction of hyperbilirubinaemia requiring phototherapy in the first week of life. Results Between April 2020 and May 2023, 742 neonates born at SMRU facilities were included in the study. A total of 695 neonates provided one to nine capillary blood samples for analysis of serum bilirubin (total 1244 tests) during the first week of life. Performance of transcutaneous bilirubinometer was assessed in 307 neonates who provided 687 paired transcutaneous capillary blood tests. Bilirubin levels were also measured in 738 cord blood samples. Adjusted values of transcutaneous bilirubinometer showed excellent agreement with capillary serum bilirubin concentration (intraclass correlation coefficient=0.923) and high sensitivity (>98%) at all clinical thresholds analysed across 3 years of sampling and multiple users. Concentrations of bilirubin detected in cord blood were not useful in identifying neonates at risk of hyperbilirubinaemia requiring treatment. Conclusions The transcutaneous bilirubinometer is a reliable tool to screen neonates and identify those needing confirmatory blood testing. Bilirubin concentrations in cord blood are not predictive of hyperbilirubinaemia in neonates.
dc.identifier.citationBMJ Paediatrics Open Vol.8 No.1 (2024)
dc.identifier.doi10.1136/bmjpo-2024-002754
dc.identifier.eissn23999772
dc.identifier.pmid39343446
dc.identifier.scopus2-s2.0-85206449756
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/101715
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleNon-invasive detection of bilirubin concentrations during the first week of life in a low-resource setting along the Thailand-Myanmar border
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85206449756&origin=inward
oaire.citation.issue1
oaire.citation.titleBMJ Paediatrics Open
oaire.citation.volume8
oairecerif.author.affiliationFaculty of Tropical Medicine, Mahidol University
oairecerif.author.affiliationMahidol Oxford Tropical Medicine Research Unit
oairecerif.author.affiliationL'Institut de Santé Globale, Genève
oairecerif.author.affiliationNuffield Department of Medicine

Files

Collections